genOway SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0004053510
EUR
2.46
-0.01 (-0.4%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 25 Million ()

stock-summary
P/E

22.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.12

stock-summary
Return on Equity

7.12%

stock-summary
Price to Book

1.41

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.14%
0%
-12.14%
6 Months
-28.9%
0%
-28.9%
1 Year
-37.56%
0%
-37.56%
2 Years
-43.96%
0%
-43.96%
3 Years
-37.32%
0%
-37.32%
4 Years
-43.96%
0%
-43.96%
5 Years
-20.39%
0%
-20.39%

genOway SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
15.48%
EBIT Growth (5y)
11.74%
EBIT to Interest (avg)
-4.83
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.03
Sales to Capital Employed (avg)
0.80
Tax Ratio
41.04%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
5.25%
Valuation key factors
Factor
Value
P/E Ratio
22
Industry P/E
Price to Book Value
1.57
EV to EBIT
-23.95
EV to EBITDA
25.85
EV to Capital Employed
1.65
EV to Sales
1.23
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-6.88%
ROE (Latest)
7.12%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by genOway SA"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 16.96% vs 22.14% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 100.00% vs 366.67% in Dec 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "20.00",
          "val2": "17.10",
          "chgp": "16.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.10",
          "val2": "0.10",
          "chgp": "2,000.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1.60",
          "val2": "0.80",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "103.00%",
          "val2": "-131.40%",
          "chgp": "23.44%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
20.00
17.10
16.96%
Operating Profit (PBDIT) excl Other Income
2.10
0.10
2,000.00%
Interest
0.10
0.10
Exceptional Items
0.00
0.00
Consolidate Net Profit
1.60
0.80
100.00%
Operating Profit Margin (Excl OI)
103.00%
-131.40%
23.44%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is 16.96% vs 22.14% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 100.00% vs 366.67% in Dec 2022

stock-summaryCompany CV
About genOway SA stock-summary
stock-summary
genOway SA
Pharmaceuticals & Biotechnology
Genoway SA is a France-based company that specializes in the provision of genetically modified mouse and rat models for biopharmaceutical companies, laboratories and research institutes. The Company offers a range of services, comprising site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). In addition, genOway SA's clients have access to its validated tool and consultancy services from a dedicated project manager. The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage. It has also formed partnerships with Charles River Laboratories, Altana Pharma, Dainihon Sumitomo Pharmceuticals and Euratools, among others.
Company Coordinates stock-summary
Company Details
Technopark 2, 31 Rue Saint Jean-de-Dieu , LYON None : 69007
stock-summary
Tel: 33 4 37654100
stock-summary
Registrar Details